Drug intelligence / Profile preview

ethinyl estradiol + cyproterone

Development stage
Phase 4
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral
01

Overview

Ethinyl estradiol + cyproterone is a fixed-dose combination oral medication containing two active ingredients: ethinyl estradiol, a synthetic estrogen, and cyproterone acetate, a synthetic progestogen with anti-androgenic properties. This combination is primarily used to treat women of reproductive age with moderate to severe acne related to androgen sensitivity or hirsutism (excessive hair growth), especially when other treatments have failed. Cyproterone acetate acts as an androgen receptor antagonist and suppresses ovarian androgen production, while ethinyl estradiol provides estrogenic activity that helps regulate the menstrual cycle and further reduces circulating androgens by increasing sex hormone-binding globulin. The combination also has contraceptive effects but should not be used solely for birth control due to an increased risk of thromboembolism compared to some other oral contraceptives[1][3][4][7].

Brand names
Diane-35Diane35Diane 35Gestra-35Gestra35Gestra 35BellgynBENAKLIN
Other names
co-cyprindiol
02

Targets

ESR2 (ERβ)PR (Progesterone receptor)AR (Adrenergic receptors)ESR1 (ERα)

Beyond the preview

Go deeper on ethinyl estradiol + cyproterone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethinyl estradiol + cyproterone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call